Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

Viewpoints: The promise and perils of prostate screening; Presidential candidates shy away from frank discussion of spending

After an exhaustive process, the U.S. Preventive Services Task Force has announced its final recommendation on PSA-based prostate cancer screening. It finds that the known harms of screening outweigh the potential benefits for men who have no cancer symptoms. It notes that all screening studies have demonstrated considerable harms associated with screening, but only one major study found evidence that screening saves lives -- and that study has some internal inconsistencies.

24 May 2012

First Edition: May 23, 2012

Today's headlines include reports about the CBO's dire predictions about a possible recession as well as details about how health policy is handled in new presidential campaign ads.

23 May 2012

Fake, substandard malaria drugs threatening gains made in fight against disease, NIH study warns

"Low-quality and fake anti-malarial drugs flooding into markets in Asia and Africa are driving drug resistance and threatening gains made in the fight against the disease in the past decade, according to a study" conducted by researchers at the National Institutes of Health (NIH) and published Monday in the journal Lancet Infectious Diseases, Reuters reports.

23 May 2012

GE Healthcare, KUH partner to drive advances in cell therapy technologies

Karolinska University Hospital Sweden and GE Healthcare Life Sciences today announced a joint research collaboration to drive advances in technologies and workflows for use in the rapidly emerging field of cell therapy.

22 May 2012

Opexa's Tovaxin for MS is now Tcelna

Opexa Therapeutics, Inc., a biotechnology company developing a novel T-cell therapy for multiple sclerosis (MS), announced today that the Company is rebranding its leading MS therapy with the new name Tcelna. The product, previously known as Tovaxin, will now be known as Tcelna as the company positions itself towards the treatment of patients with Secondary Progressive MS (SPMS).

21 May 2012

Regenerative medicine researchers explore innovative ways to treat childhood conditions

About 3 percent of the babies born in the United States have a birth defect. Children without a birth defect are also susceptible to injury or disease. At The University of Texas Health Science Center at Houston (UTHealth), regenerative medicine researchers are exploring innovative ways to treat these conditions.

21 May 2012

New supplements safety guide for athletes

The U.S. Anti-Doping Agency (USADA) recently released a new supplements safety guide for athletes as part of their "Supplement 411" initiative.

21 May 2012

WaveMark completes RFID collaboration with UMass Lowell

WaveMark, Inc., the leading provider of RFID-based supply-chain optimization solutions helping to reduce cost for hospitals and medical device manufacturers, and UMass Lowell announced that they have completed a successful collaboration to bring a new RFID product to market.

21 May 2012

Salt intake: why is it bad for you?

Many of us are aware that we shouldn’t eat too much salt. To be precise, adults should avoid eating over 6g (or around about a teaspoon of salt) a day.

21 May 2012

Vaccination studies from Mercer University to be unveiled at AAPS’ NBC

Vaccination studies from Mercer University (Ga.) headline the groundbreaking research being unveiled at the American Association of Pharmaceutical Scientists' (AAPS) National Biotechnology Conference.

21 May 2012

UK-led technologies set to transform treatments on the NHS

Video games, pioneering gene therapies and new medical devices are set to transform treatments on the NHS, with support from the Department of Health and the Wellcome Trust.

19 May 2012

BIT Companies support Rays of Hope organization to help South African children

BIT Companies, developer/manufacturer of in-vitro diagnostic, clinical and hematology instrumentation, has announced its role as a supporter of Rays of Hope, a non-profit organization in South Africa which offers sustainable aid to underprivileged children in a small village on the outskirts of Johannesburg, South Africa.

19 May 2012

USPTO issues patent to Vandalia’s process for large-scale DNA production technology

Vandalia Research, Inc. announced today that the United States Patent and Trademark Office granted U.S. Patent No. 8,163,489, covering Vandalia's process for large-scale DNA production using polymerase chain reaction.

18 May 2012

Multiple companies receive FDA approval to sell generic Plavix

The U.S. Food and Drug Administration today approved generic versions of the blood thinning drug Plavix (clopidogrel bisulfate), which helps reduce the risk of heart attack and stroke by making it less likely that platelets in the blood will clump and form clots in the arteries.

18 May 2012

Pfizer outlines vision for Systems-based Pharmaceutics

Leading pharmaceuticals company Pfizer outlined its vision for Systems-based Pharmaceutics, a revolutionary model-based approach linking drug process and product engineering to product quality and performance in the human body, at the recent Advanced Process Modelling Forum in London.

17 May 2012

Codexis receives U.S. patent for enzymes utilized in HCV therapeutics

Codexis, Inc., a developer of cost-advantaged processes for the production of biofuels, bio-based chemicals, and pharmaceutical intermediates, today announced that the United States Patent and Trademark Office (USPTO) has granted Codexis' patent covering the biocatalysts and biocatalytic processes used to make key pharmaceutical intermediates in the synthesis of leading hepatitis-C therapeutics.

16 May 2012

Bristol-Myers Squibb receives FDA approval for Devens facility to produce ORENCIA

Bristol-Myers Squibb Company announced today that the U.S. Food and Drug Administration (FDA) has approved the company's biologics manufacturing facility in Devens, Massachusetts for commercial production of ORENCIA.

16 May 2012

Avita commences enrollment in ReCell study for hypertrophic dyspigmented scars

Avita Medical Ltd.,the regenerative medicine company, today announced that it has commenced enrolment in the US FDA-approved feasibility study for the use of ReCell Spray-On-Skin in the treatment of hypertrophic dyspigmented scars.

16 May 2012

Medical Marijuana reports net income of $1.21M for first quarter 2012

Medical Marijuana, Inc., one of the medical marijuana (MMJ) industry's premier cannabis and hemp industry innovators, today announced its first quarter earnings. The company earned net income of approximately $1.21 million on gross revenues of $1.79 million for the quarter ended March 31, 2012.

16 May 2012

BiO2 Medical receives CE Mark approval for Angel Catheter to prevent PE

BiO2 Medical, Inc. a Texas based medical device manufacturer with corporate offices in San Antonio, Texas, and R&D and manufacturing operations in Golden, Colorado, announced today that it has received CE Mark approval for the Angel Catheter, a Nitinol Inferior Vena Cava (IVC) filter, permanently attached to a central venous catheter (CVC) for the use of preventing Pulmonary Embolism (PE) in critically ill patients.

16 May 2012